Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8011 to 8025 of 8981 results

  1. Atopic Dermatitis (Eczema)

    Discontinued Reference number: GID-NG10289

    NICE guideline
    Discontinued

  2. Preterm labour and birth - timing of cord clamping

    Discontinued Reference number: GID-NG10396

    NICE guideline
    Discontinued

  3. Preterm labour and birth - predicting preterm birth

    Discontinued Reference number: GID-NG10384

    NICE guideline
    Discontinued

  4. Intrapartum care for healthy women and babies - angle of episiotomy

    Discontinued Reference number: GID-NG10394

    NICE guideline
    Discontinued

  5. Workplace health - older employees

    Discontinued Reference number: GID-PHG59

    NICE guideline
    Discontinued

  6. Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]

    In development Reference number: GID-TA10684 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Ultra-radical (extensive) surgery for advanced ovarian cancer (IPG470)

    This guidance has been updated and replaced by NICE HealthTech guidance 668.

    Withdrawn guidance

  8. Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]

    Discontinued Reference number: GID-TA10851

    Technology appraisal guidance
    Discontinued

  9. Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]

    Discontinued Reference number: GID-HST10032

    Highly specialised technologies guidance
    Discontinued

  10. Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147]

    In development Reference number: GID-TA11327 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. OrganOx metra for liver transplant [ID5116]

    Discontinued Reference number: GID-TA11035

    Technology appraisal guidance
    Discontinued

  12. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]

    Discontinued Reference number: GID-TA10568

    Technology appraisal guidance
    Discontinued

  13. Secukinumab for treating giant cell arteritis in people 50 years and over [ID6563]

    In development Reference number: GID-TA11761 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Nitazoxanide for treating the common cold in people 12 years and over [ID4049]

    Discontinued Reference number: GID-TA11128

    Technology appraisal guidance
    Discontinued

  15. Nivolumab with brentuximab vedotin for treating CD30-positive relapsed or refractory classical Hodgkin lymphoma after 1 treatment line in people 5 years and over [ID6691]

    In development Reference number: GID-TA11909 Expected publication date: TBC

    Technology appraisal guidance
    In development